Hannover Rück SE HNR1.DE
Composite 55/100; the shares have moved about 20% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 18/100 — a strong mark against it.
Income ranks 89/100 — a strong point in its favour. Valuation ranks 74/100 — a moderate point in its favour. Momentum ranks 62/100 — a slight point in its favour.
Growth ranks 18/100 — a strong mark against it.
What the company does Hannover Rück SE is a global reinsurer operating in Property & Casualty and Life & Health segments, offering risk solutions across agriculture, aviation, cyber, natural catastrophes, and structured reinsurance, including parametric products. It also provides financial solutions like embedded value monetization and solvency relief.
Key financials The company reports a strong ROE of 21.7% and net margin of 11.8%, with gross and operating margins at 22.3% and 9.9%, respectively. Revenue declined -22.8% while EPS grew 48.0%, supported by a healthy dividend yield of 4.9% and payout ratio of 29.4%.
Stock health With a beta of 0.13, the stock exhibits low volatility. Momentum is mixed: +13.17% over 6 months but -4.30% below its 52-week high, and RSI(14) at 63.40 suggests modest upward pressure.
Price vs fair value The stock trades at a **discount** of 48.10% to our fair-value estimate and a **discount** of 11.35% to the analyst 12-month target. - Trading at a deep discount to fair value (379.37 vs 256.20) despite strong ROE (21.7%) and net margins (11.8%) (Valuation percentile 76.1/100). - Analyst target implies 11.35% upside, suggesting undervaluation relative to near-term expectations (Analyst 12-month target 285.29). - High income attractiveness (dividend yield 4.9%, income pillar score 93.7) may not be fully priced in.
Looking forward Forward P/E of 10.58 and PEG of 13.77 indicate potential value, though growth metrics (revenue -22.8%, growth pillar 45.5) remain a concern. Focus on capital efficiency and solvency strength may drive re-rating.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.